LONDON, July 9, 2013 /PRNewswire/ --
Allergan today announced the launch of JUVÉDERM® VOLBELLA® with Lidocaine, a new dermal filler treatment specifically tailored for the lips and the latest addition to the JUVÉDERM range of dermal fillers. This new treatment has been uniquely designed for a natural look and feel[1], with less swelling compared to other lip treatments[2], enabling patients to return to their daily life more quickly following treatment[3].
(Photo: http://photos.prnewswire.com/prnh/20130709/626430 )
"New patients are often concerned about having an unnatural result from a lip treatment - like the 'trout pouts' or 'duck lips' we sometimes see in the media. JUVÉDERM® VOLBELLA® with Lidocaine is different - it gives an ultra-smooth, natural look and can be used to tailor or enhance your smile," says Dr David Eccleston, Clinical Director of the MediZen Clinic in Sutton Coldfield. "In addition, this is the only dermal filler clinically proven to last up to 12 months in the lips with a single treatment[1† ], so it gives a long-lasting effect for my patients."
As we get older, lips can be impacted by the natural ageing process, with the appearance of more fine lines, drooping of the lip corners and a loss of volume. JUVÉDERM® VOLBELLA® with Lidocaine is designed to gently restore natural-looking lip volume, but also for defining the lip shape, treating 'downturned' or drooping lip corners, smoothing fine 'barcode' lines around the mouth and supporting the 'marionette' lines down to the chin. Developed using Allergan's proprietary VYCROSS[TM] technology, JUVÉDERM® VOLBELLA® with Lidocaine is formulated with an innovative combination of low and high molecular weight technology, which delivers an ultra-smooth gel resulting in a natural look and feel[1], as well as improved duration[1].
For women considering a dermal filler treatment in their lips, a good quality consultation with a qualified medical aesthetic practitioner, using a high quality product, can help them to achieve an enhanced, natural-looking smile.
A clinical study showed that JUVÉDERM® VOLBELLA® with Lidocaine is well tolerated and has been demonstrated to provide a smooth and natural improvement in lip fullness that lasts for up to one year[1]. In addition, the treatment is associated with high patient satisfaction, with 86% of patients reporting maintained improvement in the look and feel of their lips after 9 months and 57% of patients still reporting maintained improvement after one year[1].
About Allergan
Allergan is a multi‐specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life's potential. Today, we have approximately 10,500 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever‐evolving portfolio of pharmaceuticals, biologics, medical devices and over‐the‐counter consumer products, and state‐of‐the‐art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention and urologics, Allergan is proud to celebrate more than 60 years of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work.
Forward‐Looking Statement
This press release contains "forward‐looking statements", including but not limited to the statements by David Eccleston and statements regarding the safety, efficacy, and product availability of JUVÉDERM® VOLBELLA® with Lidocaine. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include, among other things, general industry and pharmaceutical market conditions; technological advances and patents attained by competitors; challenges inherent in the research and development and regulatory processes; challenges related to new product marketing, such as the unpredictability of market acceptance for new pharmaceutical products and/or the acceptance of new indications for such products; inconsistency of treatment results among patients; potential difficulties in manufacturing a new product; general economic conditions; and governmental laws and regulations affecting domestic and foreign operations. Additional information concerning these and other risk factors can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the U.S. Securities and
Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's 2011 Annual Report on Form 10‐K and subsequent Quarterly Reports on Form 10‐Q.
© Allergan Ltd. JUVÉDERM® is registered trademarks owned by Allergan, Inc.
Media contacts
For further information please contact:
Julia Kendrick, Allergan - kendrick_julia@allergan.com or +44-7894-597-388
Sophie Asker, Chandler Chicco Agency - s.asker@cca-uk.com or +44-(0)7909-887-208
References
1. Eccleston D. Clin, Cosmet & Investig Derma, 2012; 5:1-6
2. Allergan Data on File (Dof) Study report (Ref#DF6) 'CHLA HA Filler Study' - Fig 1, Appendix 3
3. Philipp-Dormston, WG et al. Poster presented at IMCAS, 31/01/13
† 'Single treatment' defined as initial injection with optional top-up after 14 days
UK/0748/2013
Date of Preparation: July 2013
Share this article